Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma
Authors:
Open Access
- 18 July 2018
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 103 (6) , 775-780
Abstract
Background/Aims Locally advanced (T4 per American Joint Committee on Cancer (AJCC) 8th edition) periocular basal cell carcinoma (BCC) can lead to loss of the eye. We report the neoadjuvant use of vismodegib followed by surgery in patients with such lesions with eye preservation as primary goal. Methods This retrospective interventional study includes all patients with a T4 periocular BCC (per 8th edition AJCC for eyelid carcinoma) treated by the senior author between 2013 and 2017 with neoadjuvant vismodegib prior to definitive surgery. Results Eight patients had a T4 tumour. Six patients presented with recurrent disease. Indications for neoadjuvant treatment were an unresectable tumour in one patient, an attempt to avoid an orbital exenteration in six patients and an attempt to avoid disfiguring facial surgery in one patient. Patients were treated for a median of 14 months (range: 4–36 months). All patients underwent an eye-sparing surgery following neoadjuvant vismodegib and all final surgical margins were negative for tumour. Five patients had a complete response to vismodegib with no microscopic residual BCC found during surgery; three patients had a significant partial response with residual tumour found on pathology. At last follow-up, a mean of 18 (range: 6–43) months after surgery, all patients were off-vismodegib and alive without evidence of disease. Conclusions Neoadjuvant vismodegib for locally advanced (T4) periocular BCC enabled an eye-sparing surgery in all patients in our cohort. Prolonged treatment was well tolerated by most patients. Over half of patients achieved a complete response with no residual microscopic disease. Careful long-term follow-up is needed to confirm long-term disease-free survival.Keywords
This publication has 21 references indexed in Scilit:
- Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus SyndromeAmerican Journal of Ophthalmology, 2015
- Vismodegib Resistance in Basal Cell Carcinoma: Not a Smooth FitCancer Cell, 2015
- An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinomaJournal of the American Academy of Dermatology, 2014
- Development of squamous cell carcinoma into basal cell carcinoma under treatment with VismodegibJournal of the European Academy of Dermatology and Venereology, 2014
- Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened InhibitionCancer Cell, 2014
- Vismodegib for Periocular and Orbital Basal Cell CarcinomaJAMA Ophthalmology, 2013
- Vismodegib as Eye-Sparing Adjuvant Treatment for Orbital Basal Cell CarcinomaJAMA Ophthalmology, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Globe-Sparing Surgery for Medial Canthal Basal Cell Carcinoma with Anterior Orbital InvasionOphthalmology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009